Yarrow Bioscience director lists OrbiMed warrants
Yarrow Bioscience, Inc. director Ashiya Mona reports her indirect interest in securities held by OrbiMed-managed investment funds.
Rhea-AI Filing Summary
Yarrow Bioscience, Inc. director Ashiya Mona reports her indirect interest in securities held by OrbiMed-managed investment funds. These include pre-funded warrants to acquire 4,084,827 and 583,545 shares of common stock at an exercise price of $0.0001 per share, subject to a 9.99% beneficial ownership blocker. The disclosure also describes a merger in which a VYNE Therapeutics Inc. subsidiary combined with Yarrow, after which VYNE was renamed “Yarrow Bioscience, Inc.” and each Yarrow share was exchanged for 0.7171 share of the renamed company’s common stock. The reporting person and related OrbiMed entities disclaim beneficial ownership beyond any pecuniary interest.
Positive
- None.
Negative
- None.
Insider Trade Summary
4 transactions reported
Mixed
4 txns
Insider
Ashiya Mona
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Pre-Funded Warrants (right to buy) F6, F3, F5 | -- | -- | -- |
| holding | Pre-Funded Warrants (right to buy) F6, F4, F5 | -- | -- | -- |
| holding | Common Stock F1, F2, F3, F5 | -- | -- | -- |
| holding | Common Stock F1, F2, F4, F5 | -- | -- | -- |
Holdings After Transaction:
Pre-Funded Warrants (right to buy) — 4,668,372 contracts (Indirect, See footnote);
Common Stock — 266,306 shares (Indirect, See footnote)
Footnotes (6)
- F1. Effective as of July 27, 2026 (the "Effective Time"), a wholly owned subsidiary of VYNE Therapeutics Inc. ("VYNE") merged with and into Yarrow Bioscience, Inc. ("Yarrow") with Yarrow continuing as a wholly owned subsidiary of VYNE and the surviving corporation of the merger (the "Merger") under the name "Yarrow Bioscience Operating Company Corp." In connection with the completion of the Merger, VYNE changed its name to "Yarrow Bioscience, Inc." (hereinafter, the "Issuer").
- F2. Represents the number of shares of common stock, par value $0.0001, of the Issuer ("Issuer Common Stock") received by the entities listed below in the Merger in exchange for the shares of common stock of Yarrow ("Yarrow Common Stock") held by the entities listed below prior to the Merger. Each share of Yarrow Common Stock held at the Effective Time was exchanged for 0.7171 shares of Issuer Common Stock.
- F3. These securities are held of record by OrbiMed Private Investments X, LP ("OPI X"). OrbiMed Capital GP X, LP ("GP X LP") is the general partner of OPI X. OrbiMed Capital GP X LLC ("GP X LLC") is the general partner of GP X LP. OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the managing member of GP X LLC. By virtue of such relationships, GP X, LP, GP X LLC and OrbiMed Advisors may be deemed to have voting and investment power with respect to the shares held by OPI X. OrbiMed Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI X.
- F4. These securities are held of record by OrbiMed Genesis Master Fund, L.P. ("Genesis Master Fund"). OrbiMed Genesis GP LLC ("Genesis GP") is the general partner of Genesis Master Fund. OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting and investment power with respect to shares held by Genesis Master Fund. OrbiMed Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis Master Fund.
- F5. Each of the Reporting Person, OrbiMed Advisors, GP X LLC and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a 1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, GP X LLC or Genesis GP is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.
- F6. The Pre-Funded Warrants are exercisable at any time after the date of issuance, subject to a 9.99% beneficial ownership blocker. The Pre-Funded Warrants will expire once exercised in full.
Key Figures
Warrant exercise price: $0.0001 per share
Underlying shares – pre-funded warrants: 4,084,827 shares
Underlying shares – additional warrants: 583,545 shares
+3 more
6 metrics
Warrant exercise price
$0.0001 per share
Exercise price of Yarrow Bioscience pre-funded warrants for common stock
Underlying shares – pre-funded warrants
4,084,827 shares
Common stock underlying one series of pre-funded warrants, indirect holdings
Underlying shares – additional warrants
583,545 shares
Common stock underlying another series of pre-funded warrants, indirect holdings
Beneficial ownership blocker
9.99%
Maximum beneficial ownership percentage before additional warrant exercises are blocked
Share exchange ratio
0.7171
Issuer common shares received for each Yarrow share in the merger
Effective Time of merger
July 27, 2026
Date VYNE subsidiary merged into Yarrow and the name change became effective
Key Terms
Pre-Funded Warrants (right to buy), beneficial ownership blocker, pecuniary interest, wholly owned subsidiary
4 terms
Pre-Funded Warrants (right to buy) financial
"The Pre-Funded Warrants are exercisable at any time after the date of issuance"
beneficial ownership blocker regulatory
"The Pre-Funded Warrants are exercisable at any time after the date of issuance, subject to a 9.99% beneficial ownership blocker"
A beneficial ownership blocker is a legal or structural device that prevents a shareholder from being treated as the ultimate owner of enough shares to trigger control, reporting, or voting thresholds. Think of it like a speed bump that stops an investor from reaching a stake size that would force corporate disclosure or change control rights. Investors care because it affects who controls the company, how shares vote, regulatory filings, takeover risk and therefore potential value or liquidity of their holdings.
pecuniary interest financial
"disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein"
wholly owned subsidiary regulatory
"a wholly owned subsidiary of VYNE Therapeutics Inc. merged with and into Yarrow Bioscience, Inc."
A wholly owned subsidiary is a company whose entire ownership is held by another company (the parent), so the parent controls decisions, operations, and finances. Think of it as a fully controlled branch that runs as its own legal entity but whose results flow straight into the parent’s financial statements; investors watch these structures because they affect consolidated revenue, risk exposure, and how profits, liabilities, and cash flow are allocated across the corporate group.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does Ashiya Mona’s Form 3 for VYNE disclose about Yarrow Bioscience?
It reports Ashiya Mona’s indirect interest in Yarrow Bioscience securities held by OrbiMed funds, including pre-funded warrants over 4,084,827 and 583,545 common shares at a $0.0001 exercise price, subject to a 9.99% beneficial ownership blocker and merger-related common stock holdings.
What is the exercise price of the pre-funded warrants reported for VYNE?
The pre-funded warrants can be exercised at an exercise price of $0.0001 per share of Yarrow Bioscience common stock. They are exercisable at any time after issuance, subject to a 9.99% beneficial ownership blocker, and will expire once exercised in full according to the disclosure.
What ownership cap applies to Yarrow Bioscience’s pre-funded warrants in the VYNE filing?
The pre-funded warrants are subject to a 9.99% beneficial ownership blocker. This cap limits additional exercises if doing so would push the exercising holder’s beneficial ownership above 9.99%, as described in the warrant terms referenced in the Form 3 disclosure for Yarrow Bioscience.
How did the VYNE–Yarrow merger and exchange ratio affect the reported holdings?
At the July 27, 2026 Effective Time, each Yarrow share was exchanged for 0.7171 share of the renamed Yarrow Bioscience, Inc. common stock. The reported common stock positions represent shares received in this merger by OrbiMed-affiliated entities, with indirect interests reported and beneficial ownership otherwise disclaimed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
